Rheumatoid Arthritis (RA) is a common immune disease, with early symptoms of joint morning stiffness, pain, swelling, etc., and could develop into joint deformity as the disease progresses, resulting in the loss of normal joint function, seriously affecting the patient's daily work and life. Methotrexate (MTX) is the "anchor drug" for RA treatment, which has an immunosuppressive effect, and could effectively prevent the abnormal activation of B cell in vivo, inhibit abnormal generation of cytokine, and relieve related symptoms. However, some cases reflected that single treatment of MTX is not ideal and often needed to be combined with other drugs. Iguratimod (IGU), as a new Disease Modifying Anti-Rheumatic Drug (DMARDs), is a new small molecule drug with anti-inflammatory and immunomodulatory properties, and a derivative of 7-methanesulfonylamino-6-phenoxychromones and is a hormone with two amide groups. This study provided a medical basis for the clinical therapeutic options, by exploring the combined efficacy of MTX and IGU for female patients with moderate to severe RA and its impact on ovarian function.
